rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Compass Therapeutics, Inc.

CMPX · Nasdaq

Health CareBiotechnologyNot moving yet

CMPX stood above a rising 150-day average in 26 of the last 52 weekly readings, and has been out of that trend for the last 26 weeks. It is 66.9% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 26
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$175K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
346 (+49)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 26 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$10.9M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months4
Sale orders, 12 months0
Buyers · sellers2 · 0
WhoDidSharesTraded
Neil LernerChief Accounting Officerbought20,000at $0.921 Oct 2026filed 2 Oct 2026
Neil LernerChief Accounting Officerbought2,500at $1.1424 Sep 2026filed 25 Sep 2026
Jonathan AndermanGeneral Counselbought25,000at $1.8929 Apr 2026filed 30 Apr 2026
Neil LernerChief Accounting Officerbought15,000at $1.8929 Apr 2026filed 30 Apr 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders346+49 on the quarter
New · exited97 · 50
Reported value$1.6B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
TANG CAPITAL MANAGEMENT LLCadded · filed 14 Aug 202622,990,782$110.1M+2,197,773+10.6%
ORBIMED ADVISORS LLCreduced · filed 14 Aug 202615,219,994$33.3M-1,150,646−7.0%
MONTANOVA CAPITAL, LLCreduced · filed 14 Aug 202614,101,159$30.9M-206,220−1.4%
BlackRock, Inc.added · filed 7 Aug 202612,207,172$37.8M+2,017,851+19.8%
Deep Track Capital, LPunchanged · filed 14 Aug 202612,161,496$172.1M00.0%
RTW INVESTMENTS, LPreduced · filed 14 Aug 202610,700,974$151.4M-4,118,015−27.8%
STATE STREET CORPadded · filed 7 Aug 202610,034,932$22.9M+3,259,514+48.1%
ENAVATE SCIENCES GP, LLCunchanged · filed 14 Aug 20267,788,150$17.1M00.0%
Vivo Capital, LLCreduced · filed 14 Aug 20267,757,060$17.0M-1,988,406−20.4%
BIT Capital GmbHadded · filed 12 Aug 20266,348,797$89.8M+2,857,563+81.8%
31 Mar 2023 – 30 Jun 2026
142240338Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Neil Lerner Company insiderChief Accounting Officer · last 1 Oct 20264 · 0
Jonathan Anderman Company insiderGeneral Counsel · last 29 Apr 20262 · 0
Thomas J. Schuetz Company insiderCHIEF EXECUTIVE OFFICER · last 8 Feb 202623 · 0
Arjun Prasad Company insiderChief Commercial Officer · last 2 Jan 20260 · 0
Barry Shin Company insiderCFO · last 2 Jan 20260 · 0
Carl L. Gordon Company insiderDirector · last 2 Jan 20269 · 1
Cynthia Sirard Company insiderChief Medical Officer · last 2 Jan 20260 · 0
Ellen Chiniara Company insiderDirector · last 2 Jan 20260 · 0
James P. Boylan Company insiderDirector · last 2 Jan 20260 · 0
Mary Ann Gray Company insiderDirector · last 2 Jan 20260 · 0
Philip Ferneau Company insiderDirector · last 2 Jan 20261 · 0
Richard S. Lindahl Company insiderDirector · last 2 Jan 20260 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-35.4%
Share count trendFY 2025 · to 27 Feb 20261.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$30.6M
Free cash flowFY 2025 · to 31 Dec 2025−$49.2M

Analyst forecasts

No analyst forecasts yet.